{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:40:56Z","timestamp":1780393256515,"version":"3.54.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N930019C00019"],"award-info":[{"award-number":["75N930019C00019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI157817"],"award-info":[{"award-number":["R21AI157817"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32MH080634"],"award-info":[{"award-number":["T32MH080634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is an urgent global health threat. Zoliflodacin is a novel antibiotic undergoing clinical trials for the treatment of gonorrhoea. While there are limited data regarding zoliflodacin resistance in N. gonorrhoeae, three amino acid mutations have been associated with increased MICs of zoliflodacin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the prevalence of three amino acid mutations associated with zoliflodacin resistance within a large, public database of nearly 13\u200a000 N. gonorrhoeae genomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PathogenWatch is an online genomic epidemiology platform with a public database of N. gonorrhoeae genomes. That database was used to extract gyrB sequence data and a Basic Local Alignment Search Tool (BLAST) search was performed to identify any of the three amino acid mutations in GyrB that are associated with increased zoliflodacin MICs: D429N, K450N or K450T. As a control for the search methodology, all GyrA sequences were also extracted and S91F mutations were identified and compared with the PathogenWatch database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 12\u200a493 N. gonorrhoeae genomes from the PathogenWatch database were included. Among those genomes, none was identified that harboured any of the three mutations associated with increased zoliflodacin MICs. One genome was identified to have a mutation at position 429 in GyrB (D429V).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The findings suggest that the prevalence of the three mutations associated with zoliflodacin resistance in N. gonorrhoeae is very low. However, further research into the mechanisms of zoliflodacin resistance in N. gonorrhoeae is needed. Genomic epidemiology platforms like PathogenWatch can be used to enhance the global surveillance of AMR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab262","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:11:07Z","timestamp":1625598667000},"page":"2847-2849","source":"Crossref","is-referenced-by-count":17,"title":["Using a public database of <i>Neisseria gonorrhoeae<\/i> genomes to detect mutations associated with zoliflodacin resistance"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-6458","authenticated-orcid":false,"given":"Paul C","family":"Adamson","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2800-9501","authenticated-orcid":false,"given":"Eric Y","family":"Lin","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-8329","authenticated-orcid":false,"given":"Sung-Min","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-7364","authenticated-orcid":false,"given":"Jeffrey D","family":"Klausner","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"2021101808540354300_dkab262-B1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"2021101808540354300_dkab262-B2","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021101808540354300_dkab262-B3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3201\/eid2404.171873","article-title":"Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain","volume":"24","author":"Lahra","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2021101808540354300_dkab262-B4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1473-3099(18)30340-2","article-title":"Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin","volume":"18","author":"Whiley","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021101808540354300_dkab262-B5","doi-asserted-by":"crossref","first-page":"pii=1800323","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"key":"2021101808540354300_dkab262-B6","doi-asserted-by":"crossref","first-page":"e01808-18","DOI":"10.1128\/AAC.01808-18","article-title":"Single-dose pharmacokinetics, excretion, and metabolism of zoliflodacin, a novel spiropyrimidinetrione antibiotic, in healthy volunteers","volume":"63","author":"O\u2019Donnell","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808540354300_dkab262-B7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/AAC.04124-14","article-title":"In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria","volume":"59","author":"Huband","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808540354300_dkab262-B8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2021101808540354300_dkab262-B9","doi-asserted-by":"crossref","first-page":"e01479-19","DOI":"10.1128\/AAC.01479-19","article-title":"High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017)","volume":"63","author":"Jacobsson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808540354300_dkab262-B10","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1128\/AAC.00786-15","article-title":"High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014","volume":"59","author":"Unemo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808540354300_dkab262-B11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"2021101808540354300_dkab262-B12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/AAC.04456-14","article-title":"Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae","volume":"59","author":"Alm","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808540354300_dkab262-B13","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/jac\/dkz376","article-title":"In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae","volume":"74","author":"Foerster","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021101808540354300_dkab262-B14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13073-021-00858-2","article-title":"A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at Pathogenwatch","volume":"13","author":"S\u00e1nchez-Bus\u00f3","year":"2021","journal-title":"Genome Med"},{"key":"2021101808540354300_dkab262-B15","year":"2020"},{"key":"2021101808540354300_dkab262-B16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/1471-2105-10-421","article-title":"BLAST+: architecture and applications","volume":"10","author":"Camacho","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"2021101808540354300_dkab262-B17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/bioinformatics\/btp163","article-title":"Biopython: freely available Python tools for computational molecular biology and bioinformatics","volume":"25","author":"Cock","year":"2009","journal-title":"Bioinformatics"},{"key":"2021101808540354300_dkab262-B18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2105-5-113","article-title":"MUSCLE: a multiple sequence alignment method with reduced time and space complexity","volume":"5","author":"Edgar","year":"2004","journal-title":"BMC Bioinformatics"},{"key":"2021101808540354300_dkab262-B19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41564-019-0501-y","article-title":"The impact of antimicrobials on gonococcal evolution","volume":"4","author":"S\u00e1nchez-Bus\u00f3","year":"2019","journal-title":"Nat Microbiol"},{"key":"2021101808540354300_dkab262-B20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12864-020-6511-6","article-title":"Genomic evolution of Neisseria gonorrhoeae since the preantibiotic era (1928\u20132013): antimicrobial use\/misuse selects for resistance and drives evolution","volume":"21","author":"Golparian","year":"2020","journal-title":"BMC Genomics"},{"key":"2021101808540354300_dkab262-B21","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: the universal protein knowledgebase in 2021","volume":"49","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2021101808540354300_dkab262-B22"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2847\/40641289\/dkab262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2847\/40641289\/dkab262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:19:43Z","timestamp":1634761183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/11\/2847\/6330665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,29]]},"published-print":{"date-parts":[[2021,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab262","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,7,29]]}}}